A single dose of dalteparin effectively prevents clotting during haemodialysis

Nephrology Dialysis Transplantation

Volumn 14, Issue 8, 1999, Pages 1943-1947

  Sagedal, Solbjørg ^a   Hartmann, Anders ^a   Sundstrøm, Kristina ^a   Bjørnsen, Stine ^a   Fauchald, Per ^a   Brosstad, Frank ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anti FXa; Anticoagulation; Clotting; Dalteparin; Haemodialysis; Single dose

Indexed keywords

DALTEPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD FLOW; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HEMODIALYSIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; ULTRAFILTRATION;

ADULT; AGED; ANTICOAGULANTS; BLOOD COAGULATION; DALTEPARIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 0032794346     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/14.8.1943     Document Type: Article

References (17)

1. Ljungberg B, Jacobson SH, Lins IE, Pejler G. Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane. Clin Nephrol 1992; 38: 97-100
2. Suzuki T, Kazuo O, Naganuma S et al. Clinical application of Fragmin (FR-860) in hemodialysis: multicenter cooperative study in Japan. Semin Thromb Hemost 1990; 16: 46-54
3. Schrader J, Stibbe W, Armstrong W et al. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988; 33: 890-896
4. Schrader J, Valentin R, Tønnis HJ et al. Low molecular weight heparin in hemodialysis and hemofiltration patients. Kidney Int 1985; 28: 823-829
5. Pham PT, Miller JM, Demetrion G, Lew SQ. Clotting by heparin of hemoaccess for hemodialysis in an end-stage renal disease patient. Am J Kidney Dis 1995; 25: 642-647
6. Salzman E, Rosenberg R, Smith M, Lindon J, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73
7. Holmer E. Anticoagulant properties of heparin and heparin fractions. Scand J Haematol 1980; [Suppl. 25]: 25-39
8. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332(20): 1330-1335
9. Deuber HJ, Schulz W. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991; 40: 496-500
10. Schmitt Y, Schneider H. Low-molecular-weight heparin (LMWH): influence on blood lipids in patients on chronic haemodialysis. Nephrol Dial Transplant 1993; 8: 438-442
11. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992; 22: 359-374
12. Bratt G, Tørnebohm E, Widlund L, Lockner D. Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42: 613-620
13. Grau E, Siguenza F, Maduell F et al. Low molecular weight heparin (CY-216) versus unfractionated heparin in chronic hemodialysis. Nephron 1992; 62: 13-17
14. Bern MM, Lokich JJ, Wallach SR et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. Ann Intern Med 1990; 112: 423-428
15. Twardowski ZJ. The clotted central vein catheter for haemodialysis. Nephrol Dial Transplant 1998; 13: 2203-2206
16. Wanner C, Zimmermann J, Quaschning T, Galle J. Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int 1997; [Suppl. 62]: S53-55
17. De Lima JJG, Sesso R, Abensur H et al. Predictors of mortality in long-term haemodialysis patients with a low prevalence of comorbid conditions. Nephrol Dial Transplant 1995; 10: 1708-1713